Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)

A method of modifying the activation status of lung immune cells, modulating lymphocyte distribution in the tumor microenvironment or preventing tumor-infiltrating lymphocyte (TIL) exhaustion in the tumor microenvironment in a patient suffering from a non-small cell lung cancer (NSCLC) which coexists with chronic obstructive pulmonary disease (COPD) comprising:

• (i) identifying the patient as a patient suffering from a non-small cell lung cancer (NSCLC) which coexists with chronic obstructive pulmonary disease (COPD);
• and (ii) administering to said patient a therapeutically effective amount of an immune checkpoint inhibitor.

7-9. (canceled)

A method of treating a patient suffering from non-small cell lung cancer (NSCLC), comprising

• i) determining whether the patient has a coexisting chronic obstructive pulmonary disease (COPD) and
• ii) administering an immune checkpoint inhibitor to a subject identified as having a coexisting chronic obstructive pulmonary disease.

A method of treating a patient suffering from a non-small cell lung cancer (NSCLC) that coexists with chronic obstructive pulmonary disease (COPD) comprising i) determining the expression level of PD-L1 in a tumor tissue sample obtained from the patient ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of a PD-1 inhibitor when the level determined at step i) is higher than the predetermined reference value.

(canceled)